Company / Interest Expense
BioMarin Pharmaceutical Interest Expense History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$17.3M
FY2023
5-year range
$15.3M / $17.3M
FY2019-FY2023
Trend
+8.5%
vs FY2022
Sector context
#20 of 44
Health Care
What the data says
At $17M, BioMarin Pharmaceutical's interest expense ranks #25 of 44 in the Health Care sector. Interest Expense has fluctuated over the past 8 years, ranging from $15M in FY2021 to $44M in FY2018.
Based on SEC 10-K filings.
$17M in FY2023 with a 5-year CAGR of -16.9%.
Increased from $15M to $17M over the past 2 years.
Health Care sector context is included.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -16.1%
- 5-Year CAGR
- -16.9%
- 10-Year CAGR
- -
Sector benchmark
#25 of 44 in Health CareTop 55% of 44This company $17.3M Sector average $291.0M
▼
-94.0% below sector average
Key checks
Key Insights
- 5-year CAGR of -16.9%, indicating a declining trend.
- In FY2023, interest expense increased 8.5% year-over-year.
- Ranks #20 out of 44 companies in the Health Care sector.
- Peak interest expense was recorded in FY2018.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $17.3M | +8.5% |
| FY2022 | $16.0M | +4.1% |
| FY2021 | $15.3M | -47.7% |
| FY2020 | $29.3M | +24.9% |
| FY2019 | $23.5M | -46.3% |
| FY2018 | $43.7M | +2.2% |
| FY2017 | $42.7M | +8.1% |
| FY2016 | $39.5M | +3.3% |
As of FY2023 · SEC 10-K · Updated Jul 2, 2026